Wed, Mar 4, 2015, 5:45 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Financial News From Zacks Small Cap Research

  • SNWV: Eagerly Await DMC Rec in April Zacks Small Cap Research - 2 hours 0 minutes ago

    By Brian Marckx, CFA OBB:SNWV Q4 / Full-Year 2014 Financial Results, Operational Update   SANUWAVE (OBB:SNWV) reported financial results for the fourth quarter and year-ending 12/31/2014 and provided a ...

  • On February 10, 2015, Amarantus Bioscience Holdings, Inc. (AMBS) announced the publication of Phase 2a results of eltoprazine for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID) in Brain – A Journal of Neurology entitled: “Eltoprazine Counteracts L-DOPA-induced Dyskinesias in Parkinson's Disease: …

  • In December, 2013, SNGX (SNGX) initiated the Phase II study of SGX942 for the treatment of oral mucositis in head and neck cancer patients. This Phase II trial is a randomized, double-blind, dose-ranging, placebo-controlled trial, initially set to enroll approximately 75 subjects across three SGX942 dose groups and placebo, …

  • TNXP: Healthy Cash Balance And Multiple Catalysts Should Drive Tonix Shares Higher Zacks Small Cap Research - Tue, Mar 3, 2015 9:52 AM EST

    By Jason Napodano, CFA NASDAQ:TNXP On March 3, 2015, Tonix Pharmaceuticals (NASDAQ:TNXP) reported  financial results  for the fourth quarter and full year ending December 31, 2014. In the press release, ...

  • NTRP: Neurotrope Targeting Alzheimer's, Orphan Indications With Bryostatin-1 Zacks Small Cap Research - Mon, Mar 2, 2015 12:45 PM EST

    Below, we give a brief overview of bryostatin-1, the Phase 2a study, the next step in the development of bryostatin-1 for Alzheimer’s disease. Alzheimer’s disease (AD) is the most common form of dementia in older adults.

  • SNGX: Updated Preclinical Data on RiVax Presented Zacks Small Cap Research - Mon, Mar 2, 2015 12:25 PM EST

    In February, 2015, Soligenix (SNGX) presented new preclinical study data that demonstrated the efficacy and safety of its heat-stabilized ricin toxin vaccine (RiVax™) in a non-human primate (NHP) lethal aerosolized ricin exposure model.  The data was presented in a poster session at the American Society of Microbiology …

  • BLU.TO: Kiacta Phase 3 Remains On Track For Bellus Health Zacks Small Cap Research - Mon, Mar 2, 2015 10:10 AM EST

    On February 25, 2015, Bellus Health, Inc. (BLU.TO) (BLUSF) reported financial results for the fourth quarter and full year for 2014 (all financials in Canadian dollars). Revenues for the fourth quarter totaled $1.06 million, compared to $0.75 million in the corresponding period of 2013, and consisted mostly of revenue …

  • ATOS: Two Deals: Key Steps toward the Official Launch of FullCYTE Breast Aspirator Zacks Small Cap Research - Mon, Mar 2, 2015 9:00 AM EST

    In Feb, 2015, Atossa (ATOS) announced two important deals with the two large, prestigious diagnostic companies in the US as the company prepares for the official launch of its FullCYTE Breast Aspirator nationwide. The deal with Thermo Fisher Scientific was announced in early Feb and the deal with Henry Schein Medical was …

  • CBMX: Testing Volumes Jump, Big Beat on EPS Zacks Small Cap Research - Fri, Feb 27, 2015 8:50 AM EST

    By Brian Marckx, CFA NASDAQ:CBMX Q4 Financial Results: Softer Avg Reimbursement More Than Offset By Huge Jump in Testing Volumes...  CombiMatrix (NASDAQ:CBMX) announced financial results for the fourth ...

  • GTMAY: Energy Reform: Long-Term Positive, Despite Short-Term Uncertainty Zacks Small Cap Research - Thu, Feb 26, 2015 4:00 PM EST

    On August 11, 2014, Mexico’s President Enrique Peña Nieto signed energy reform legislation that is intended to open Mexico’s oil and natural gas markets to foreign direct investment. Mexico’s goal is to attract international companies interested in Mexico's untapped reserves. Mexico has the biggest unexplored crude area …

  • Inuvo (INUV) is an emerging player in the digital advertising space. It is digital publishing and advertising technology company.

  • Why You Should Own Cipher Pharmaceuticals Zacks Small Cap Research - Thu, Feb 26, 2015 11:05 AM EST

    On February 25, 2014, Cipher Pharmaceuticals (CPHR) reported financial results for the fourth quarter and full year ended December 31, 2014. Backing out this one-time milestone payment, revenues from continuing operations at Cipher actually increased 18% year-over-year. Revenues in the fourth quarter were driven by $5.9 …

  • ICAD: High Margin Services Driving Strong Top-Line Zacks Small Cap Research - Wed, Feb 25, 2015 3:15 PM EST

    By Brian Marckx, CFA NASDAQ:ICAD Q4 / Full-Year 2014 Results:  Revenue In-Line and Up Double-Digits in Both Detection and Therapy  iCAD Inc. (NASDAQ:ICAD) announced financial results for the fourth quarter ...

  • QCRH: Very Good Fourth Quarter Despite Outsized Loss Provision Zacks Small Cap Research - Wed, Feb 25, 2015 9:15 AM EST

    By Ann Heffron, CFA, CPA NASDAQ:QCRH Compared to the year-ago quarter, QCRH (NASDAQ:QCRH) fourth quarter net earnings fell 3% to $3.0 million from $3.1 million after preferred stock dividends. On a diluted ...

  • Depomed: The Next Big Specialty Pharma Success Story Zacks Small Cap Research - Tue, Feb 24, 2015 12:30 PM EST

    On February 23, 2015, Depomed, Inc. (DEPO) reported financial results for the fourth quarter and full year ended December 30, 2014. In October 2014, Depomed amended its agreements with Salix and Valeant, which eliminated any and all continuing obligations on the part of Depomed in the manufacture and supply of Glumetza …

  • CPKF: Fourth Quarter Beats Estimate Zacks Small Cap Research - Tue, Feb 24, 2015 11:42 AM EST

    By Ann Heffron, CFA, CPA OTC:CPFK CPKF’s (OTC:CPKF) fourth quarter net earnings rose $0.4 million year over year, or 36%, to $1.6 million, while 2014’s fourth quarter diluted EPS grew by $0.11, or 35%, ...

  • ITKG: Expanding Capacity Ahead of Anticipated Demand to Avert Bottlenecks Zacks Small Cap Research - Mon, Feb 23, 2015 1:00 PM EST

    Under the terms of the contract, ElectriPlast will provide engineering and design services, materials and finished products to East Penn. The company received a $150,000 payment from East Penn and has recorded 80% of that over the past two quarters. Integral also recognized $12,500 of license revenue, as it amortizes the …

  • TAIPF: Taipan Resources to plug and abandon Badada-1 well on Block 2B in Kenya Zacks Small Cap Research - Mon, Feb 23, 2015 1:00 PM EST

    Though the reaction appears excessive, we have reduced our rating to Neutral and our target to $0.13.

  • CIIX: Optimistic About Strategy to Serve an Underserved and Fast Growing Market Zacks Small Cap Research - Fri, Feb 20, 2015 4:10 PM EST

    We are optimistic about ChineseInvestors.com (CIIX), which provides financial news, analysis and commentary on U.S. stocks and markets in Chinese through its websites, chineseinvestors.com and chinesefn.com and its YouTube channel chinesefn, among other media platforms. Management believes this market is underserved and …

  • The decrease in revenue was attributable to lower royalty revenue primarily from Pennsaid and Pennsaid 2% net sales in the U.S. market. As such, cash and investments on hand as of March 31, 2015 should still be approximately $55 million, or in excess of $5.00 per share.

  • PBIO: NIH SBIR Phase II Grant Boosts Balance Sheet in a Non-dilutive Way Zacks Small Cap Research - Fri, Feb 20, 2015 9:20 AM EST

    By Grant Zeng, CFA OTC:PBIO On February 19, 2015, PBIO (OTC:PBIO) announced that it has been awarded a $1.02 million SBIR Phase II grant from the National Human Genome Research Institute of the National ...

  • ROSG: Broad Patent Allowances Assure Sustainable Growth Zacks Small Cap Research - Fri, Feb 20, 2015 9:00 AM EST

    Recently, Rosetta Genomics (ROSG) received a Notice of Allowance from the US Patent and Trademark Office for a patent claiming the use of miR-34a for the treatment of p53-associated cancers. The miR-34a patent covers a core element of Rosetta Genomics’ microRNA technology in the development of cancer therapeutics relating …

  • PRGB: High Margin Services Business Driving Top-Line Zacks Small Cap Research - Wed, Feb 18, 2015 8:45 AM EST

    By Brian Marckx, CFA OBB:PRGB Full Year 2014 Results: Mostly In-Line With Our Estimates, Services Biz Picking Up Steam…  Protea (OBB:PRGB) filed their 10-K for the full-year ending December 31.  While ...

  • During the second quarter demand in the Middle East was very strong as inventory levels declined from the high levels caused by record crops in Australia. The company will have to increase its available acreage to fill potential orders from Canada and the State of Washington.

  • AEMD: U.S. Study Kicks Off, Ebola Looks Promising Zacks Small Cap Research - Wed, Feb 11, 2015 3:30 PM EST

    In September 2014 AEMD announced that they were awarded the year-4 DARPA contract which will pay the company $669k if all three milestones are met.  DARPA has the option of entering into the remainder of the proposed contract, that is, for year five. AEMD recently noted that due to budget restrictions, DARPA has reduced …

  • CDTI: Paris, France to control diesel truck entry into the city due to pollution. Zacks Small Cap Research - Wed, Feb 11, 2015 9:15 AM EST

    The mayor of Paris has proposed a ban most diesel engined vehicles from the city by 2020 in order to lower air pollution. Paris is one of the largest, and most popular tourist destination, in Europe. One of the problems, not discussed by the Mayor, is that diesel cars are very popular in Europe and large trucks (all of …

  • ARWR: Arrowhead Reports Fiscal 1Q15 Financial Results Zacks Small Cap Research - Wed, Feb 11, 2015 9:00 AM EST

    The big jump was primarily attributable to the increased spending in clinical trials, drug manufacturing for clinical trials, and drug toxicity studies during the three months ended December 31, 2014.

  • ZMS.V: Lawsuit Resolution Opens Up Inflection Opportunity in 2015 Zacks Small Cap Research - Tue, Feb 10, 2015 4:00 PM EST

    By Brian Marckx, CFA OTC:ZMSPF TSX:ZMS.V Resolution of lawsuit, significant development progress bodes well for revenue inflection in 2015   By several measures 2014 was a disappointing year for Zecotek ...

  • CRRS: Updated Outlook Zacks Small Cap Research - Tue, Feb 10, 2015 12:00 PM EST

    By Marla Backer NASDAQ:CRRS Recent events increase the risk of holding shares of Corporate Resource Services (NASDAQ:CRRS), in our view. They have dropped 77.5% year-to-date versus a -0.2% decline for ...

  • APDN Reports 108% Revenue Growth for Fiscal 1Q15 Zacks Small Cap Research - Tue, Feb 10, 2015 12:00 PM EST

    APDN reported record revenue of $1.24 million for the fiscal 1Q15, an increase of 108% from fiscal 1Q14 and an increase of 92% compared to the prior quarter ended September 30, 2014. The device can identify the presence of an APDN DNA-mark on products before they are sampled or sent for forensic authentication.

  • NBIX: CRF Drug Offers Another Shot on Goal For Catalyst Rich Neurocrine Bio Zacks Small Cap Research - Tue, Feb 10, 2015 10:00 AM EST

    The company did not have any revenues for the quarter, as expected. Neurocrine reported a net loss of $19.4 million, or $0.26 per share in the quarter, roughly in-line with our modeling that was looking for a loss of $0.25 per share. The net loss in 2014 was composed of $46.4 million in research and development expenses …

  • CFRX: Our Initial Look At ContraFect - We Like What We See Zacks Small Cap Research - Mon, Feb 9, 2015 3:00 PM EST

    Lysins degrade (lyse) bacterial cell walls from the inside, resulting in the bursting of the bacteria. Lysins are delivered to the infected area and lyse the bacterial cell wall from the outside. Lysins are highly evolved enzymes that are able to target one of the five bonds in peptidoglycan (murein), the main component …

  • SMLR: Solid Q4 With Revenue Up 35% Zacks Small Cap Research - Fri, Feb 6, 2015 3:10 PM EST

    By Brian Marckx, CFA NASDAQ:SMLR Q4 2014 Results:   Revenue Up 35% yoy, 18% Sequentially and 11% Ahead of Our Estimate  Semler Scientific (NASDAQ:SMLR) turned in a strong Q4, particularly on the top line, ...

  • CYRX Revenue Guidance of +150% - 200%! Zacks Small Cap Research - Fri, Feb 6, 2015 9:30 AM EST

    CryoPort (CYRX) announced results for their 2015 fiscal third quarter ending December 31st.  While revenue was slightly softer than our estimate, the numbers were far from disappointing and indicate that the business continues to pick up steam.  This is evidenced by thirteen straight quarters of yoy revenue growth and eight …

  • Since all company owned locations are also self storage facilities there was an increased in room count and square footage in the self storage business. The company has decided to build and expand existing self storage facilities rather than buying new outlets.

  • VCEL: Why Vericel Shares Will Double In 2015 Zacks Small Cap Research - Thu, Feb 5, 2015 2:00 PM EST

    On January 15, 2015, we had a chance to sit down for a face-to-face meeting with the senior management team at Vericel Corporation (VCEL). At the meeting, management laid out their plans for generating growth and driving profitability at the Cell Therapy and Regenerative Medicine (CTRM) business newly acquired from Sanofi …

  • ADXS Outlines Clinical Development Plan for its Pipeline Zacks Small Cap Research - Thu, Feb 5, 2015 9:35 AM EST

    On Feb 3, ADXS (ADXS) held its Analyst & Investor Day in New York City. At this conference, the company and experts in the field of immunotherapy presented updates on its ongoing clinical trials of three candidates: ADXS-HPV, ADXS-PSA and ADXS-cHER2. The company has multiple Phase I or Phase II clinical programs targeting …

  • EQUR: Wound Healing With Electrical Stimulation Zacks Small Cap Research - Tue, Feb 3, 2015 5:00 PM EST

    E-QURE Corp. (Electric Quick Ulcer Remedy), a publicly traded company (EQUR) headquartered in New York, is a premier provider of innovative medical devices in the field of active advanced wound management.  EQUR has developed an effective, low cost, easy-to-use device for chronic wound management, which addresses a market …

  • CTSO: FDA Greenlights U.S. Cardiac Surgery Study Zacks Small Cap Research - Tue, Feb 3, 2015 12:30 PM EST

    By Brian Marckx, CFA NASDAQ:CTSO FDA Approves Cardiac Surgery Feasibility Study  FDA’s approval for CytoSorbents (NASDAQ:CTSO) to conduct a feasibility study comes about one month after the company submitted ...

  • PBSV: Q4 Revenue In-Line, Beat on EPS Zacks Small Cap Research - Mon, Feb 2, 2015 9:15 AM EST

    By Brian Marckx, CFA OTC:PBSV Fiscal Q4 2014 Results: Revenue In-Line, Beat on EPS From Cost Control   Pharma Bio-Serv (OTC:PBSV) reported financial results for the fiscal fourth quarter ending October ...

  • NRI.TO: WF10 Fails Phase 2 Allergic Rhinitis Study Zacks Small Cap Research - Fri, Jan 30, 2015 11:30 AM EST

    On January 30, 2015, Nuvo Research Inc. (NRI.TO) (NRIFF) announced results of its Phase 2 allergic rhinitis study in Germany failed to demonstrate statistically significant separation of WF10 vs. placebo. We are disappointed with the results given the previous Phase 2 data with WF10 that had showed very nice separation …

  • ANTB: AntriaBio Prepares For Clinical Study Of Once Weekly Insulin Zacks Small Cap Research - Wed, Jan 28, 2015 11:00 AM EST

    The company has been very busy over the past month securing financing and completing preclinical PK/PD studies in hope to advance its lead candidate, AB101, into human clinical trials later this year. AntriaBio is developing AB101, a product that aims to be the first once-weekly basal insulin. AB101 is a formulation of …

  • By Steven Ralston, CFA OTC:GRDH Guardian 8 Holdings (OTC:GRDH)  is the developer and manufacturer of the  G8 Pro V2 , a non-lethal security device designed for use in the professional security industry. ...

  • SANW: Company sells land and pays down some convertible debt. Zacks Small Cap Research - Mon, Jan 26, 2015 11:15 PM EST

    On Jan. 26, 2015 the company (SANW) announced the sale of two properties in California for an aggregate of $7.3 million, the pay down of a mortgage of $2.3 million and the redemption of $5 million of the recently issued convertible debenture. The two properties sold were 759 acres in Calipatria in the Imperial Valley and …

  • SDIG: New Initiatives Could Further Differentiate Offering and Help Drive Ad Revenue Zacks Small Cap Research - Fri, Jan 23, 2015 11:30 AM EST

    As an emerging Internet radio and digital media platform, StationDigital aspires to become the first device agnostic, multimedia global broadcast platform offering a broad range of entertainment choices in a free-to-consumer service. We are optimistic about initiatives StationDigital announced this week, including creating …

  • CBMX: Overhyped Risks Provide Attractive Entry Point Zacks Small Cap Research - Thu, Jan 22, 2015 9:35 AM EST

    The lawsuit was dismissed by the court later in 2011.  An appeals court reversed this decision in late 2012 and the case was remanded to the Superior Court of California.  Strathman filed an amended complaint and, following an unsuccessful motion by CBMX for the court to rule in their favor without a trial, on January 6, …

  • LMD.V: Revenue +240% in 2014, +90% in 2015? Zacks Small Cap Research - Thu, Jan 22, 2015 9:20 AM EST

    By Brian Marckx, CFA TSX:LMD.V OTC:LEDIF 2014 Revenue Preannouncement: $9.7M In Orders, In-Line w/ Expectations, Should Recognize $8.5M in 2014 This morning (1/21/2015) LED Medical (TSX:LMD.V) (OTC:LEDIF) ...

  • PBIO: With Boosted Balance Sheet, PBIO Ready to Accelerate Sales Zacks Small Cap Research - Wed, Jan 21, 2015 1:30 PM EST

    We noticed that all of the Company's officers and board members participated in the transaction. - One warrant to purchase 500 shares of common stock at an exercise price of $0.3125 per share, with a term expiring on November 12, 2017.

  • NVIV: InVivo Patient No.1 Shows ‘Unexpected’ Gains Zacks Small Cap Research - Wed, Jan 21, 2015 1:00 PM EST

    On January 21, 2015, InVivo Therapeutics (NVIV) provided an update on the status of the first patient enrolled in the company’s ongoing pilot study of its investigational Neuro-Spinal Scaffold (NSS) for the treatment of acute spinal cord injury. This is primarily a safety study (NCT02138110), with the main goal to evaluate …

  • Lion Biotech: An Emerging Biotech Company Focused On TIL Therapy for Cancers Zacks Small Cap Research - Tue, Jan 20, 2015 2:15 PM EST

    In December 2014, Lion Biotechnologies (LBIO) named Elma Hawkins, PhD to serve as its new president and chief executive officer, effective January 1, 2015. Dr. Hawkins is a veteran in the biopharmaceutical industry. Dr. Hawkins has served as Lion’s president and chief operating officer since August 2014.  From February …

Next >>